cyrilzakka/clinical-trials huggingface dataset:
Clinical Outcomes of Slow Developing Blastocysts

This study evaluates which transfer strategy will result in a higher probability of pregnancy in patients whose single best day 5 embryo resulting from an IVF cycle is classified as expansion grade \<4 by Gardner and Schoolcraft classification. All cycles will be cultured to day 6 and half the patients will undergo a fresh embryo transfer and the other half a frozen embryo transfer.

A lack of established markers for predicting blastocyst development increases the risk of having no embryos or embryos not-fully expanded available for transfer. Slower but non-arrested embryos are frequently found to have progressed to blastocyst stage by the time of a day 6 transfer. In the absence of a receptive endometrium, embryo selection for fresh transfer may be futile, and cryopreservation could be a better option. The objective is to determine which transfer strategy will result in a higher probability of pregnancy in patients whose single best day 5 embryo resulting from an IVF cycle is classified as expansion grade \<4 by Gardner and Schoolcraft classification. The investigators hypothesize that in bad prognosis patients with slow-developing blastocysts, vitrified-warmed embryo transfer will result in higher implantation, clinical and ongoing pregnancy and live birth rates than fresh embryo transfer.

Eligibility Criteria:
Inclusion Criteria:

* All IVF cycles undergoing autologous fresh blastocyst embryo transfer
* All IVF cycles in which the best available embryo for transfer is at expansion grade \<4
* All ages

Exclusion Criteria:

* Ovum Donation cycles
* Preimplantation genetic testing cycles
Evaluation of Residual Urine After Intermittent Catheterisation

Intermittent catheterization is a well-known method used for emptying the bladder. The objective of this study is to compare the residual urine after intermittent catheterisation with 2 different, hydrophilic coated, intermittent catheters. The study is a randomized, single blinded, crossover study including 24 healthy males.


Eligibility Criteria:
Inclusion Criteria:

* Male
* 18 years and above
* A negative urine dip-stick
* Have signed informed written consent to participate

Exclusion Criteria:

* The test participant has previous or current congenital deformity, diseases or operation in the lower urinary tract
Type 2 Diabetes Secondary Prevention

Three hundred and ninety height diabetic patients were educated during a week of hospitalisation (nutritional and physical-activity advices). After that, they were randomized in two groups : frequent follow-up (each three month) by educational nurses and dieteticians, versus no follow-up (control group). All patients were evaluated one year after their inclusion,by HbA1c (primary outcome), anthropometry, other cardiovascular risk factors, nutritionnal and physical-activity behaviours.


Eligibility Criteria:
Inclusion Criteria:

* type 2 diabetes patient aged \>=18 years

Exclusion Criteria:

* incapacity to a moderate physical activity
Acupuncture Therapy for COVID-Related Olfactory Loss

This study is looking at the role of acupuncture as a treatment for olfactory dysfunction in patients who tested positive for COVID-19.


Eligibility Criteria:
Inclusion Criteria:

* 18 years or older.
* Patients with post-viral olfactory dysfunction \> 4 weeks.
* History of positive COVID-19 PCR.

Exclusion Criteria:

* Less than 18 years of age.
* Active sinus infection.
* New diagnosis of untreated CRS.
* Prior diagnosis of dementia or Parkinson's disease.
* Prior head trauma or neurosurgical procedure resulting in olfactory loss.
* Patients who do not speak or read English.
* Patients unable to understand and sign the study consent.
Novartis Vaccine and Diagnostics Carriage Trial

The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal vaccines on carriage of Neisseria meningitidis in a young adult population.


Eligibility Criteria:
Inclusion Criteria:

* Healthy subjects, 18-24 years of age who provided written informed consent at the time of enrollment;
* Subjects who were available for all the visits scheduled in the study;
* Subjects who were in good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator.

Exclusion Criteria:

* History of any serogroup B meningococcal vaccine administration;
* Current or previous, confirmed or suspected disease caused by N. meningitidis;
* Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;
* Significant acute or chronic infection within the previous 7 days or fever (defined as oral temperature ≥38ºC) within the previous day;
* Antibiotics within 3 days (72 hours) prior to enrollment;
* Pregnancy or nursing (breastfeeding) mothers;
* Females of childbearing age who had not used or did not plan to use acceptable birth control measures, for the 12 months duration of the study. Oral, injected or implanted hormonal contraceptive, diaphragm, condom, intrauterine device or sexual abstinence were considered acceptable forms of birth control. If sexually active the subject must have been using one of the accepted birth control methods for at least 30 days prior to study entry;
* Any serious chronic or progressive disease (e.g., neoplasm, diabetes, cardiac disease, hepatic disease, progressive neurological disease or seizure disorder; autoimmune disease, human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS), or blood dyscrasias or diathesis, signs of cardiac or renal failure or severe malnutrition);
* Known or suspected impairment/alteration of the immune system, immunosuppressive therapy, including use of corticosteroids in immunosuppressive doses or chronic use of inhaled high-potency corticosteroids within the previous 60 days. \[Use of topical corticosteroids administered during the study in limited areas (i.e., eczema on knees or face or elbows) of the body were allowed\]; use of immunostimulants;
* Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;
* History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component;
* Participation in another clinical trial within the last 90 days or planned for during study;
* Family members and household members of research staff;
* Any condition which in the opinion of the investigator and/or the Regional MD may interfere with the evaluation of the study objectives.
Urdu Translation and Validation of Michigan Hand Outcome Questionnaire

Aim of this study to provide a urdu version of Michigan Hand Outcome Questionnaire, that will be more understandable for Pakistani People.

Because of these unique qualities, the MHQ has become one of widely used tools by the clinicians to assess quality-of-life relevant to functioning of hands and upper limb. It has also been translated to many other languages from the original English version for an easy understanding and adaptation into the local population. despite being its availability in approximately 20 different languages., the Urdu translation of this questionnaire has not yet been published anywhere. Urdu is Pakistan's official language, and the majority of Pakistanis are unable to understand this subjective assessment questionnaire originally written in English. It is required to translate the questionnaire into Urdu for Pakistanis people as the upper limb disorders are one of the most prevalent musculoskeletal disorders in Pakistan. Urdu translation of Michigan Hand Outcomes Questionnaire will help the Pakistan population with hand disorders to describe their pain or disability experience clearly. The Clinical physiotherapists of Pakistan can be capable of capturing the subjective health states of Pakistani patients with hand disorders more conveniently using the Urdu translated MHQ.

Eligibility Criteria:
Inclusion Criteria:

* • Patients with conditions and diseases of the Hand and the Upper extremity (arthritis, trauma etc.).

  * Both genders of age 18 and over
  * Patients who are willing to fill study questionnaires.

Exclusion Criteria:

* • Unable to read or write in Urdu

  * People with cognitive dysfunction
  * People with Any neurological disorder
  * Unable to fill questionnaire independently
Online Grammatical Reasoning Training for Older Adults

The START study will investigate the impact of playing a Grammatical Reasoning brain training task on overall brain function (cognition) and day-to-day function in people over 50.

The study builds on existing work that has shown very promising results with brain training approaches in older adults. There is good evidence that playing brain training games leads to improvements in brain functions including memory and reasoning. There is also a suggestion that regular involvement in brain training games might help reduce the risk of cognitive decline and dementia later in life. It appears that reasoning, or problem-solving, is particularly important as it is one of the first abilities to decline with age. This study will use this evidence to target reasoning in a specific brain training task. It will also explore the potential role of genetic factors in how people perform in the task.

The study will compare the impact of a Grammatical Reasoning Task (START) with a control task consisting of simple picture-matching. Over 7000 participants will be randomly allocated to either START or the control and will be asked to play the task as often as they wish for a period of six weeks. Both tasks will be delivered entirely online so people will access the study from home on their computers. This will be achieved through our dedicated online research platform, PROTECT, which hosts a cohort of over 20,000 older adults who have provided DNA samples as part of a longitudinal study.

This study will measure the impact of the training on cognition and Instrumental Activities of Daily Living. Assessments will be completed online at baseline, two/six weeks and six months. Overall, this study aims to generate exciting new data about how brain training could be included in guidance on healthy ageing.


Eligibility Criteria:
Inclusion Criteria:

* Adults over 50
* Access to a computer with a keyboard and the internet
* Participant registered on the PROTECT study

Exclusion Criteria:

* Diagnosis of dementia
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

This is a single center, prospective randomized double blind, parallel and placebo controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks. We will also, testing whether Linagliptin is an insulin sensitizer.

This is a single center, prospective randomized double blind, parallel and placebo-controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks. The study enrolls type 2 patients with diabetes.

Eligibility Criteria:
Inclusion Criteria:

Age 20-80 years inclusive. Type 2 diabetes BMI ≥30 kg/m2 Subjects on statins, ACE inhibitors, thiazolidinediones and antioxidants will be allowed as long as they are on stable doses of these compounds and the dosage in not changed during the course of study.

HbA1c ≤ 8.0%

Exclusion Criteria:

- Use of GLP-1 agonists or DPP-IV therapy in the last 3 months. History of Pancreatitis. Risk for pancreatitis, i.e., history of gallstones, alcohol abuse, and hypertriglyceridemia.

Subjects who are taking antiplatelet or anticoagulant medications will be excluded from the fat biopsy portion of the study.

Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass, surgery or coronary angioplasty) in the previous four weeks Hepatic disease (liver function tests more than 3 times the upper limit of normal) Renal impairment (serum eGFR \<30 ml/min) Any other life-threatening, non-cardiac disease Uncontrolled hypertension (BP \> 160/100 mm of Hg) Congestive Heart Failure class III or IV. Use of an investigational agent or therapeutic regimen within 30 days of study Participation in any other concurrent clinical trial
Safety and Efficacy of Sodium Nitrite in Sickle Cell Disease

This study will determine if administration of sodium nitrite is safe and can improve small vessel blood flow and tissue oxygenation when given as an additional treatment in patients with acute vaso-occlusive crisis (pain crisis) associated with sickle cell disease.

Nitric oxide (NO) is a naturally occuring chemical that relaxes blood vessels and helps improve blood flow.

The pain associated with vaso-occlusive crisis (pain crisis) in sickle cell disease is caused in part by lack of oxygen and increased tissue acid because blood flow is blocked by stiff sickle red cells. Administration of sodium nitrite should generate nitric oxide in this area of hypoxia and acidosis and improve blood flow.

Eligibility Criteria:
Inclusion Criteria:

Subjects meeting all of the following criteria will be considered for admission to the study:

1. Male or female subject aged between 8 and 23 years of age; only patients up to the age of 23 will be studied at Childrens Hospital Los Angeles
2. Electrophoretic diagnosis of sickle cell disease;
3. Sudden onset of acute pain involving \>=1 sites typical of vaso-occlusive crisis (Vaso-occlusive crisis is defined as acute, severe pain in the extremities, chest, abdomen, or back that can not be explained by other complications of sickle cell disease or by a cause other than sickle cell disease.);
4. Severe pain requiring parenteral analgesics and hospitalization.
5. Informed consent obtained from a legal representative or from subjects 18 years of age or older before enrollment;
6. Being willing and able to be followed for at least 30 days for evaluation.

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

1. Clinically significant bleeding;
2. Current drug abuse or participation in methadone program;
3. Episode of pain requiring hospitalization within 2 weeks prior to current admission;
4. Other complications of sickle cell disease including cerebrovascular accident, pulmonary hypertension, or seizure;
5. Pregnancy (confirmed by a serum human chorionic gonadotropin pregnancy test) or breast feeding;
6. Blood pressure less than 25th percentile for the subject's age and sex on admission or at the time of screening;
7. Methemoglobinemia \>3%;
8. Anemia with hemoglobin level less than 6 g/dL;
9. Red blood cell G6PD deficiency, by laboratory testing prior to enrollment;
10. History of allergy to nitrites or allergy to other substances characterized by dyspnea and cyanosis;
11. Treatment with allopurinol, a medication that could interfere with nitrite metabolism, within the past 30 days before screening;
12. Treatment with any investigational drug within the past 30 days;
13. Significant acute or chronic concomitant diseases (including renal, hepatic, cardiovascular, pulmonary, or oncologic disease, sepsis, pulmonary edema, pulmonary embolism) that would be inconsistent with survival for at least 6 months;
14. Any subject judged by the clinical investigator or study manager to be inappropriate for the study.
Novaferon in Non-hospitalized Adult Patients With Mild COVID-19

An Adaptive, Multicenter, Randomized, Double-blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Aerosolized JH509 vs. Placebo in Non-hospitalized Adult Patients with Mild COVID-19


Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent has been obtained from the participants with an age of over 20 years at the time of signing the informed consent.
2. SARS-CoV-2 infection is diagnosed by RT-PCR within 72 hours before starting drug administration.
3. Less than six days from onset of COVID-19-related symptoms below to starting the administration of the investigational drug with at least one of the following symptoms observed at the time of enrollment : fever (37.5C or higher), respiratory symptoms (cough, shortness of breath, sore throat, runny nose, etc.), headache, myalgia, malaise, abdominal pain, diarrhea, nausea/vomiting, dysosmia, dysgeusia, or other COVID-19 symptoms defined by investigators or coinvestigators investigators.
4. Oxygen saturation (SpO2) measured by pulse oximeter is more than 95%.
5. Require no supplemental oxygen.
6. Women (less than 12 months after the last menstrual period) who have a negative pregnancy test (urine hCG qualification) and agree to use highly effective contraceptive methods (taking oral contraceptives or use of condom by male partner) during the study period. Investigators or coinvestigators investigators will provide guidance on contraceptive methods.
7. Women who are not breast-feeding.

Exclusion Criteria:

1. History of hypersensitivity to interferon or JH509 or any excipients of interferon or JH509.
2. Have received antiviral treatments and drugs expected to have antiviral effects (Favipiravir, Remdesivir, Interferon, Nafamostat mesilate, and Basiliximab/Imdevimab, including drugs that are being newly developed and that have been approved) in the past or having had it considered necessary to receive these treatments during the study period.
3. Having had it considered necessary to receive treatments, such as drugs containing corticosteroids (excluding topical drugs), antimicrobial agents, and inhalants other than the investigational drug during the study period.
4. Taking "Shosaikoto," an herbal medicine.
5. Neuropsychiatric disorder and autoimmune disorder.
6. CTCAE Grade 3 or higher liver dysfunction (ALT/AST \> 5ULN) or renal dysfunction (eGFR \< 30 mL/min/1.73 m2).
7. Active infections or other medical conditions that contraindicate inhalation therapy.
8. Having the complication of malignant tumor or a history of malignant tumor within 1 year before consent acquisition.
9. Inappropriate for inclusion in the clinical trial as determined by investigators or coinvestigators investigators.
PRISM Registry: Pseudobulbar Affect Registry Series

PBA is a neurologic condition that is estimated to impact over a million patients and their families in the United States. PBA occurs secondary to an otherwise unrelated neurologic disease or injury, and manifests as involuntary, frequent, and disruptive outbursts of crying and/or laughing. Progress has been made in better understanding this debilitating condition, but much more needs to be done. That's why a new PBA patient registry, PRISM (Pseudobulbar Affect RegIstry Series), has been initiated.

The goal of PRISM is to establish the prevalence and quality of life (QOL) impact of PBA in patients with underlying neurologic conditions including

* Alzheimer's disease
* Amyotrophic lateral sclerosis
* Multiple sclerosis
* Parkinson's disease
* Stroke
* Traumatic brain injury

Because this is an observational registry, it doesn't require you to intervene with any specific treatment or procedure. Your participation allows the PRISM registry to collect and analyze data from your site and also compare it to national numbers captured in the PRISM registry about PBA across all of the major at-risk neurologic populations.


Eligibility Criteria:
Inclusion Criteria:

* All participants must have underlying neurologic conditions known to be risk factors of PBA: Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's Disease, Stroke, and Traumatic Brain Injury.
* The population for this study will be 18 years and over
Adequacy of Perioperative Cefuroxime Dosage According to the BMI

This study evaluates the dosage of perioperative cefuroxime for obese patients. Dosage was increased if the BMI was over 30kg/m\*m and as well over 50kg/m\*m. Drug levels were measured in blood and tissue.

Cefuroxime is an often used antibiotic for surgery antibiotic prophylaxis to avoid surgical wound infection. In this study the dosage of cefuroxime was adjusted to the BMI:

less than 30kg/m\*m: 1,5g 31-50kg/m\*m: 3,0g more than 50kg/m\*m: 4,5g

Cefuroxime was applicated 30 to 60 minutes before the begin of surgery. Drug Levels in blood and fat tissue were measured at skin cut (30-60 minutes after application of Cefuroxime), 45 minutes after skin cut (75-105 minutes after minutes after application of Cefuroxime) and at the end of surgery (up to 150 minutes after application of Cefuroxime) .

The hypothesis of this study is that adequate drug levels are reached in all groups.

Eligibility Criteria:
Inclusion Criteria:

* elective laparoscopic Intervention
* BMI \< 90 kg/m\*m
* age: 18-85 years

Exclusion Criteria:

* known history of allergy to cefuroxime or other cephalosporines
* absent consent skill
* elective open surgery
* preoperative therapy with antibiotics
* patient's denial of the study
Identification and Clinical Efficacy Analysis of Biomarkers in Sepsis Patients

Sepsis, a severe response to bacterial infection, lacks understanding of immunometabolic features that can identify high-risk patients. This study aimed to discover immune, biological, and metabolic biomarkers in sepsis patients with poor prognosis and understand the underlying mechanisms of host immune responses.

Sepsis is a life-threatening condition resulting from a dysregulated host response to infection and remains a significant global health crisis. Accurately identifying high-risk patients and understanding the underlying mechanisms of distinct host responses are crucial. Dysregulation of immune and biological responses, along with metabolic remodeling, has emerged as a prevalent characteristic in sepsis patients. However, there is still a need for a comprehensive understanding of specific markers related to immunometabolism and the underlying mechanisms contributing to the disturbance in sepsis pathogenesis.

This study aims to investigate the immune, biological, and metabolic profiles of sepsis patients, focusing on the alteration of metabolism in sepsis patients with poor outcomes. The findings of this study will provide valuable insights into dysregulated immunometabolism, shedding light on its contribution to the potentiation of immunopathogenesis in sepsis.

Eligibility Criteria adults over the age of 19 a sepsis patient in ICU

Patients are excluded from the study If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a Do not resuscitation(DNR) patient a patient under the age of 18

Outcome Measure ICU mortality, 28 days mortality Use of inotropics, vasopressors CRRT(continuous renal replacement therapy), ECMO (Extracorporeal membrane oxygenation), Interventional lung assist, polymyxin

Eligibility Criteria:
Inclusion Criteria:

* adults over the age of 19 a sepsis patient in ICU

Exclusion Criteria:

* If the patient or care giver does not agree to participate in the study a bone marrow transplant or an organ transplant patient a DNR patient a patient under the age of 18
Granulocyte Transfusions in Hematological Patients With Febrile Neutropenia

The investigators retrospectively evaluated the efficacy of granulocyte transfusions as adjunctive treatment for severe infections in neutropenic fever unresponsive to antimicrobial therapy in hematological patients.


Eligibility Criteria:
Inclusion Criteria:

* fever;
* presence of absolute neutrophil count \<0.5 x 10\^9/L
* evidence of bacterial or fungal infections (including clinical signs of infection, positive cultures or biopsy, and radiological evidences)
* unresponsiveness to appropriate antimicrobial therapy for at least 48 hours

Exclusion Criteria:

* none